More than halfway through 2023, we’ve seen plenty of movement in the personnel department across medtech. Last July, we broke down the biggest personnel moves in medtech so far in 2022. That was followed up by the full-year report in December. Through more than eight months, the changes atop medtech companies continue to arrive. Some […]
Dexcom
Dexcom more than doubles profits on 25% sales growth in Q2
Dexcom shares are up today on second-quarter results that topped the consensus forecast. Shares of DXCM rose 2.3% at $132.35 apiece after the market closed yesterday. By the next afternoon, DXCM shares were up more than 4% to $134.71 apiece. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies […]
Dexcom CCO Teri Lawver says new sensor is ‘first step’ to expand addressable market
Teri Lawver joined Dexcom as chief commercial officer just as the company got set for a massive commercial undertaking. The FDA cleared the company’s next-generation Dexcom G7 continuous glucose monitor (CGM) in December 2022. One month later, Lawver assumed the position of CCO. Within about a month, she was set to oversee the U.S. launch […]
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Dexcom aims to bring new glucose sensor to the market for people who don’t use insulin
Dexcom (Nasdaq:DXCM) today unveiled its strategy to expand access to its glucose-sensing technology for millions around the world. San Diego-based Dexcom held an Investor Day event in which it revealed plans to bring a new product to market in the U.S. in 2024. The company designed its new product for people who don’t use insulin […]
The top IVD innovation news stories of 2023 — so far
This year is proving to be another important year for innovation in the in vitro diagnostic (IVD) space. According to the FDA, IVD devices are tests performed on samples taken from the human body. They could be everything from blood tests processed in labs to home COVID-19 or pregnancy tests to continuous glucose monitors using […]
Dexcom study shows diabetes’ impact on mental health
A new study commissioned by Dexcom found that diabetes has significant negative effects on mental health. The study revealed that 84% of people surveyed agree that having diabetes can negatively impact mental health. It also demonstrated that nearly all participants (91%) believe technology enables a balanced lifestyle while managing diabetes. Dexcom, a maker of continuous […]
Dexcom touts more clinical evidence for G6 CGM in Japan
Dexcom (Nasdaq:DXCM) announced that it showcased its Dexcom G6 CGM at the 66th Annual Meeting of the Japan Diabetes Society. G6, now the previous-generation version of the company’s CGM after the launch of the G7, uses a small, wearable sensor. It also features a transmitter, continuously measuring and sending glucose levels wirelessly to a smart […]
UK study backs Dexcom real-time CGM
Dexcom (Nasdaq:DXCM) announced today that a published study in the UK supports its real-time continuous glucose monitoring (rtCGM). San Diego-based Dexcom published its study in Diabetes Therapy. It’s titled “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.” The […]
Dexcom proposes $1B offering of convertible senior notes
Dexcom (Nasdaq:DXCM) today announced that it intends to offer $1 billion in convertible senior notes due in 2028. The continuous glucose monitor (CGM) maker made its private placement to persons reasonably considered qualified institutional buyers. San Diego-based Dexcom also plans to grant the initial purchasers of the notes an option to buy more. Those options […]
Dexcom grows revenues 18% in Street-beating Q1, raises guidance
Dexcom (Nasdaq:DXCM) today announced that it’s raising its 2023 financial guidance following strong first-quarter financial results. Shares of DXCM dipped 3.7% to $119 apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.2%. The San Diego-based continuous glucose monitor […]